Emerge Diagnostics Inc.

Emerge Diagnostics has developed an FDA-registered, class-II diagnostic device called an Electrodiagnostic Functional Assessment (EFA) that can age and evaluate muscle activity, distinguish between acute versus chronic injury, and objectively quantify effort. The EFA-Soft Tissue Management (STM) Program is a patent-pending process that has been specifically designed for an employer’s current workforce, as well as new hires, in compliance with ADAAA and EEOC regulations. It begins with a baseline assessment, which is not read, but instead is stored in a secured database. When a work-related injury is reported, a post-injury assessment is performed, at which time the information collected from the baseline assessment is compared to the data from the post-injury assessment. The baseline data is read only if an injury occurs and the post-loss assessment is performed. The EFA-STM Program allows employers to establish pre-injury status and provides the objective data necessary to accurately diagnose soft-tissue injuries which ultimately leads to better treatment outcomes for employees and patients. Please sign up for our mailing list to periodically receive exciting invitations and information from Emerge Diagnostics: http://eepurl.com/bCKCk5